Nastorazepide | Z-360 | CAS#209219-38-5 | gastrin and CCK-2 receptor antagonist

MedKoo Cat#: 206018 | Name: Nastorazepide (Z-360)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nastorazepide, also known as Z-360, is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells.

Chemical Structure

Nastorazepide (Z-360)

CAS#209219-38-5

Theoretical Analysis

MedKoo Cat#: 206018

Name: Nastorazepide (Z-360)

CAS#: 209219-38-5

Chemical Formula: C29H36N4O5

Exact Mass: 520.2686

Molecular Weight: 520.62

Elemental Analysis: C, 66.90; H, 6.97; N, 10.76; O, 15.37

Price and Availability

Size	Price	Availability
5mg	USD 150.00	Ready to ship
10mg	USD 250.00	Ready to ship
25mg	USD 450.00	Ready to ship
50mg	USD 750.00	Ready to ship
100mg	USD 1,250.00	Ready to ship
200mg	USD 2,050.00	Ready to Ship
500mg	USD 3,650.00	Ready to Ship
1g	USD 4,950.00	Ready to Ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Z360; Z-360; Z 360; Nastorazepide.

IUPAC/Chemical Name

(R)-3-(3-(5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid

InChi Key

VIJCCFFEBCOOIE-JOCHJYFZSA-N

InChi Code

InChI=1S/C29H36N4O5/c1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37/h7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)/t22-/m1/s1

SMILES Code

O=C(O)C1=CC=CC(NC(N[C@@H]2CN(C3CCCCC3)C4=CC=CC=C4N(CC(C(C)(C)C)=O)C2=O)=O)=C1

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#S8S08C10

QC Data

View QC data: current batch, Lot#S8S08C10

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Nastorazepide (Z-360) is a selective 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist.

In vitro activity:

To determine the antagonistic effect of Z-360 on the CCK-2 receptor, the intracellular Ca2+ release was measured. Whereas 1 nmol/l CCK-8 increased intracellular Ca2+ release by CHO-K1/CCK-2 cells, pretreatment with Z-360F (10−11 to 10−5 mol/l) inhibited CCK-8-induced intracellular Ca2+ release in a concentration-dependent manner (IC50 value: 11 nmol/l, Fig. 3). However, Z-360F at 10−5 mol/l showed no effect on Ca2+ release in CHO-K1/CCK-2 cells without CCK-8 stimulation. As the degree of the Ca2+ release from unstimulated CHO-K1/CCK-2 cells is similar to untransfected cells (intact CHO-K1 cells), we defined as basal activity using unstimulated CHO-K1/CCK-2 cells. As Z-360F alone did not increased calcium release in CHO-K1/CCK-2 cells comparing to basal activity, it was considered that Z-360 did not act as agonist activity for classical CCK-2 receptor, at least at range of 10−5 M from 10−11 M. These results demonstrated that Z-360 shows selective antagonistic activity for the human CCK-2 receptor without an agonistic activity for CCK-2 receptor. Reference: Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. https://dx.doi.org/10.1007/s00280-007-0591-8

In vivo activity:

MiaPaCa2 cells were injected subcutaneously into the right flanks of nude mice and allowed to establish for 14 days. Z-360 was then administered orally to the mice at doses of 10, 30, or 100 mg/kg once daily for 21 days. Z-360 significantly inhibited tumor growth as measured by both tumor size (Fig. 4a) and tumor weight (Fig. 4b) in a dose-dependent manner. As shown in Fig. 4b, administration of Z-360 at 10, 30, and 100 mg/kg resulted in 16.5, 39.6, and 41.7% inhibition of final tumor weight, respectively. This dose-dependent inhibitory activity was significant at doses of 30 mg/kg (P < 0.05) and 100 mg/kg (P < 0.01). Reference: Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. https://dx.doi.org/10.1007/s00280-007-0591-8

	Solvent	mg/mL	mM
Solubility
	DMSO	32.0	61.50

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 520.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

In vivo protocol:

1. Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, Tanaka T, Takei M, Watson SA. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. doi: 10.1007/s00280-007-0591-8. Epub 2007 Sep 28. PMID: 17901954. 2. Orikawa Y, Kato H, Seto K, Kobayashi N, Yoshinaga K, Hamano H, Hori Y, Meyer T, Takei M. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice. Mol Pain. 2010 Oct 28;6:72. doi: 10.1186/1744-8069-6-72. PMID: 20979661; PMCID: PMC2987997.

1: Kato H, Seto K, Kobayashi N, Yoshinaga K, Meyer T, Takei M. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8. doi: 10.1016/j.lfs.2011.07.019. Epub 2011 Aug 3. PubMed PMID: 21839751. (Last Update: 4/20/2016)